title: Rituximab in the spondyloarthropathies: data of eight patients followed up in the French Autoimmunity and Rituximab (AIR) registry.
authors.forename: G
authors.initials: G
authors.lastname: Nocturne
authors.forename: M
authors.initials: M
authors.lastname: Dougados
authors.forename: A
authors.initials: A
authors.lastname: Constantin
authors.forename: C
authors.initials: C
authors.lastname: Richez
authors.forename: J
authors.initials: J
authors.lastname: Sellam
authors.forename: A
authors.initials: A
authors.lastname: Simon
authors.forename: D
authors.initials: D
authors.lastname: Wendling
authors.forename: X
authors.initials: X
authors.lastname: Mariette
authors.forename: J-E
authors.initials: JE
authors.lastname: Gottenberg
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008875:Middle Aged; D056687:Off-Label Use; D000069283:Rituximab; D025242:Spondylarthropathies / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D000069283:Rituximab